| 2026年中报 | 2025年年报 | 2025年中报 | 2024年年报 | 2024年中报 | |
|---|---|---|---|---|---|
| 营业收入(元) | |||||
| 临床阶段(元) | - | - | - | 1,766,779,126.83 | 799,447,873.63 |
| 商业化阶段(元) | - | - | - | 2,803,949,393.96 | 1,395,943,785.47 |
| 新兴服务(元) | - | - | 756,017,543.57 | 1,226,373,500.56 | 499,946,931.26 |
| 小分子CDMO解决方案(元) | 2,296,947,262.80 | 4,734,651,275.52 | 2,429,080,191.41 | - | - |
| 新兴业务(元) | 1,304,053,909.91 | 1,929,129,448.38 | - | - | - |
| 营业成本(元) | |||||
| 临床阶段(元) | - | - | - | 1,070,280,234.84 | 467,054,341.87 |
| 商业化阶段(元) | - | - | - | 1,308,953,865.20 | 692,266,703.95 |
| 新兴服务(元) | - | - | 530,804,003.34 | 960,670,424.45 | 398,532,323.57 |
| 小分子CDMO解决方案(元) | 1,198,337,744.51 | 2,517,242,168.72 | 1,268,260,282.44 | - | - |
| 新兴业务(元) | 880,236,370.66 | 1,348,162,449.42 | - | - | - |
| 毛利(元) | |||||
| 临床阶段(元) | - | - | - | 696,498,891.99 | 332,393,531.76 |
| 商业化阶段(元) | - | - | - | 1,494,995,528.76 | 703,677,081.52 |
| 新兴服务(元) | - | - | 225,213,540.23 | 265,703,076.11 | 101,414,607.69 |
| 小分子CDMO解决方案(元) | 1,098,609,518.29 | 2,217,409,106.80 | 1,160,819,908.97 | - | - |
| 新兴业务(元) | 423,817,539.25 | 580,966,998.96 | - | - | - |
| 毛利率(%) | |||||
| 临床阶段(%) | - | - | - | 39.42 | 41.58 |
| 商业化阶段(%) | - | - | - | 53.32 | 50.41 |
| 新兴服务(%) | - | - | 29.79 | 21.67 | 20.29 |
| 小分子CDMO解决方案(%) | 47.83 | 46.83 | 47.79 | - | - |
| 新兴业务(%) | 32.50 | 30.12 | - | - | - |
| 收入构成(%) | |||||
| 临床阶段(%) | - | - | - | 30.48 | 29.66 |
| 商业化阶段(%) | - | - | - | 48.37 | 51.79 |
| 新兴服务(%) | - | - | 23.74 | 21.15 | 18.55 |
| 小分子CDMO解决方案(%) | 63.79 | 71.05 | 76.26 | - | - |
| 新兴业务(%) | 36.21 | 28.95 | - | - | - |
| 毛利构成(%) | |||||
| 临床阶段(%) | - | - | - | 28.35 | 29.22 |
| 商业化阶段(%) | - | - | - | 60.84 | 61.86 |
| 新兴服务(%) | - | - | 16.25 | 10.81 | 8.92 |
| 小分子CDMO解决方案(%) | 72.16 | 79.24 | 83.75 | - | - |
| 新兴业务(%) | 27.84 | 20.76 | - | - | - |